8-KOther Events

BIOGEN INC. 8-K Report (Apr 15, 2003)

Filed April 15, 2003For Securities:BIIB

Summary

This 8-K filing from IDEC Pharmaceuticals Corporation, dated April 15, 2003, primarily serves to announce the company's financial results for the first quarter ended March 31, 2003. The report includes a press release detailing these results, filed as an exhibit. Investors should review this press release for specific financial performance indicators, revenue figures, and any commentary on the company's operational and financial condition during the period. While this filing itself is brief and largely procedural, it is crucial for understanding IDEC's financial trajectory early in 2003. The attached press release will contain the core financial data, allowing investors to assess the company's performance against expectations and historical trends. The filing also confirms compliance with Regulation FD, ensuring that material information is broadly disseminated.

Key Highlights

  • 1IDEC Pharmaceuticals Corporation filed an 8-K on April 15, 2003.
  • 2The filing's primary purpose is to announce Q1 2003 financial results.
  • 3Exhibit 99.1 contains the press release with the detailed financial results.
  • 4The report is furnished under Regulation FD disclosure (Item 9).
  • 5The filing confirms the company's principal executive offices are in San Diego, California.
  • 6Edward M. Rodriguez, VP of Finance and Controller, signed the report on behalf of the company.

Frequently Asked Questions

The main purpose of this 8-K filing is to publicly announce IDEC Pharmaceuticals Corporation's financial results for the first quarter ended March 31, 2003, through an attached press release.

The specific financial details for the first quarter of 2003 are contained within the press release filed as Exhibit 99.1 to this Form 8-K.

This filing primarily focuses on the disclosure of Q1 2003 financial results and related financial condition commentary. Other significant new material information beyond the financial performance is not explicitly detailed in the 8-K itself, but would be found within the press release.

Regulation FD (Fair Disclosure) ensures that material information is disclosed to all investors simultaneously. In this case, IDEC is using the 8-K filing to publicly disseminate its quarterly financial results, adhering to these regulations.